Please login to the form below

Not currently logged in
Email:
Password:

NICE set to reject Pfizer's Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits
NICE

The National Institute for Health and Care Excellence has ruled that Pfizer's first-in-class breast cancer therapy Ibrance (palbociclib) is not a cost-effective use of NHS resources.

In draft guidance, the UK's watchdog said that while Ibrance has been shown to stall disease progression for an average of 10 months more than the current treatment standard, more clinical evidence is required to quantify overall survival improvement.

Ibrance is a first-line CDK 4/6 inhibitor designed to halt tumour cell growth and delay progression, and is the first oncology therapy that increases the effect of aromatase inhibitors to do so.

It won EU approval in November 2016 for treatment of hormone receptor positive, HER2-negative, locally advanced metastatic breast cancer, and was licensed by the FDA two months ahead of schedule in February 2015.

An estimated 5,500 people in England would be eligible for treatment with Ibrance, however a full course of treatment currently costs £79,650 per patient.

Prof Carole Longson, director of the centre for health technology assessment at NICE, said: “The committee needs more evidence of the drug's impact on overall survival of people with breast cancer. However, even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price.

“The committee heard from the patient expert that delaying the progression of their cancer for as long as possible and being able to continue with normal activities, including working, is valued very highly by patients and their families.

“It also heard that by postponing disease progression, palbociclib may reduce the number of people who are exposed to the often unpleasant side effects of chemotherapy, and delay the need for such treatment in others.

“Taking the costs into account, the committee concluded that it could not recommend palbociclib for NHS use at present.”

NICE's initial verdict is open to public comment until 24 February, and while it is not minded to back Ibrance now, the guidance does state that patients already receiving the drug should continue to have access to it.

Article by
Rebecca Clifford

2nd February 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....